



29 January 2024

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

Dear Shareholder

HERAMED LIMITED ENTITLEMENT OFFER - NOTIFICATION TO INELIGIBLE SHAREHOLDERS

Pursuant to the rights issue offer booklet released to ASX on 18 January 2024 (**Offer Booklet**), the Company is undertaking a non-renounceable pro-rata entitlement issue of 1 new Share for every 5 existing Shares held by Eligible Shareholders on the Record Date, at an issue price of \$0.02 per New Share to raise up to approximately \$1.28 million (before costs) (**Entitlement Offer**) on the terms described in the Offer Booklet.

Details of the Entitlement Offer are contained in the Offer Booklet. The Offer Booklet can be accessed from the ASX and Company websites www.asx.com.au and <https://www.hera-med.com/investor-relations> respectively.

The Entitlement Offer is only made to and capable of acceptance by shareholders of the Company with a registered address in Australia or New Zealand at 7.00pm (AEDT) on 23 January 2024 (**Record Date**). The records of the Company indicate that you did not have a registered address in Australia or New Zealand at the Record Date.

Noting the above, in accordance with ASX Listing Rule 7.7.1(b), the Company hereby advises that it will not be offers new Shares under the Entitlement Offer to you. You will not receive a copy of the Offer Booklet and the entitlement and acceptance form and no new Shares under the Entitlement Offer will be offered to you.

If you have any questions, please contact the Company at the details set out below.

--ENDS--

Authorised by the Board of HeraMED Limited.

For more information please contact:

HeraMED Limited
Executive Chairman
Dr Ron Weinberger
M: +61 406 384 189
E: ron@hera-med.com

Company Secretary
Jonathan Hart
E: Jonathan@hera-med.com

Investor Relations
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

-ENDS-